Today: 30 June 2026
KLA stock week-ahead: KLAC steadies near $1,500 as earnings, Fed loom

KLA stock week-ahead: KLAC steadies near $1,500 as earnings, Fed loom

New York, Jan 25, 2026, 16:36 EST — Market closed.

  • KLA shares closed Friday up 0.85%, slipping a bit in after-hours trading.
  • The chip-tool maker is set to release its fiscal Q2 results after Thursday’s close.
  • A Federal Reserve ruling due midweek may shake up high-growth tech and semicap stocks.

KLA Corp shares ended Friday up 0.85% at $1,512.78 but slipped 0.18% after hours to $1,510.01. During the session, the stock fluctuated between $1,451.82 and $1,512.97, showing notable volatility ahead of a busy week of catalysts.

KLA is set to release its Q2 fiscal 2026 results after the U.S. market closes Thursday, with a conference call at 2 p.m. PT. The company provides process-control and yield-management equipment that chipmakers use to detect defects and boost production. Its earnings often offer clues about wafer fab investment trends.

Wall Street expects growth, with analysts forecasting earnings per share to climb roughly 7% and revenue to increase about 6% compared to last year, according to Yahoo Finance data. For KLA, even slight tweaks to its outlook can sway the stock sharply, as investors zero in on the company’s “guidance” — viewing it as the key to the story. Yahoo Finance

Rates remain a key factor. The Fed meets Jan. 27-28, and the policy decision drops Wednesday. Any unexpected shift in the statement or during Chair Jerome Powell’s press conference could shake semiconductors, as investors adjust the discount rate they apply to future earnings.

Friday’s key business survey revealed persistent price pressures, fueling doubts about the pace of inflation easing. “Increased costs, widely blamed on tariffs, are again cited as a key driver of higher prices,” said Chris Williamson, chief business economist at S&P Global Market Intelligence, in the report. Reuters

KLA won’t be the sole focus for chip investors this week. Earnings reports are due from several mega-cap tech giants and ASML, the chip-equipment heavyweight. These results typically influence forecasts for AI-driven capital expenditures and the speed of new fab projects.

Traders tracking KLA will focus on order momentum in advanced logic and memory, shifts in service demand, and whether management detects customers accelerating or delaying purchases. Insights on lead times and backlog often carry as much weight as the main figures.

Margins remain a sticking point. KLA has focused on higher-value systems and software, yet costs could surge fast if customers change their order mix or if parts and labor remain constrained.

But there’s a downside risk. A more cautious forecast, weaker customer spending signals, or new shocks from trade and export regulations could weigh on sentiment. That’s especially true if the Fed shows less appetite for loosening policy.

Coming up, the Fed will announce its policy decision on Wednesday, Jan. 28. Then, KLA reports earnings after Thursday’s close, with a 2 p.m. PT call scheduled for Jan. 29.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Theravance Biopharma (TBPH) Slides 3% After $929M Zymeworks (ZYME) Deal Announced
    June 30, 2026, 10:24 AM EDT. Theravance Biopharma (TBPH) shares slipped about 3% on June 29, 2026, after Zymeworks (ZYME) said it would buy the company in an all-cash deal valued at around $929 million. The deal is set to close in H2 2026. Theravance went up for sale after its main drug, ampreloxetine, missed in Phase III trials. Most of Theravance's revenue came from a single COPD collaboration. The buyout gives shareholders $17 per share, which is a 22% premium to the March 3 close, plus CVRs linked to future ampreloxetine proceeds. Management called the move the best route for shareholder value as operational cuts and slow growth continue. Theravance has a Zacks Rank #4 (Sell).
Exxon stock price: XTO’s Eagle Ford sale push puts XOM in play ahead of key week
Previous Story

Exxon stock price: XTO’s Eagle Ford sale push puts XOM in play ahead of key week

AAPL stock jumps nearly 3% as Morgan Stanley flags iPhone 17 strength ahead of Apple earnings
Next Story

AAPL stock jumps nearly 3% as Morgan Stanley flags iPhone 17 strength ahead of Apple earnings

Go toTop